A peripherally restricted cannabinoid 1 receptor agonist provides analgesic benefit from neuropathic pain and a lack of addiction-related behavior
Amie L. Severino, Lindsay M. LueptowiD, Emily Ellis, Dania Alkoraishi, Igor SpigelmaniD, Catherine M. CahilliD
Abstract
IntroductionCannabis is increasingly used for pain management, with many patients reporting relief from chronic pain that did not respond to conventional treatments. However, cannabis is also associated with unwanted side effects including psychomimetic effects and the potential of developing a cannabis use disorder. To circumvent the central nervous system effects, we investigated whether a peripherally restricted cannabinoid receptor (CB1) agonist, PrNMI [(4-{2-[-(1E)-1[(4-propylnaphthalen-1-yl)methylidene]-1H-inden-3yl]ethyl}morpholine] attenuated pain hypersensitivity associated with nerve injury and profiled its abuse potential. Materials and MethodsMice with chronic constriction injury (CCI) of the sciatic nerve developed hypersensitivity to mechanical stimulation. Paw withdrawal thresholds were assessed following administration of PrNMI (i.p. 0.3 mg/kg and 0.6 mg/kg) or vehicle in CCI and sham mice. The conditioned place preference model was used to measure drug-reward to 0.6 mg/kg i.p. PrNMI in CCI and sham-injury control animals. We further assessed abuse potential to determine if PrNMI (0.5 mg/kg) would reinstate drug-seeking behavior in mice trained to self-administer intravenous fentanyl (10 g/kg/infusion). ResultsPrNMI administration transiently increased paw withdrawal thresholds in mice with CCI-induced allodynia in a dose-dependent manner. PrNMI conditioning did not produce a conditioned place preference in mice with either CCI or sham injury. Mice who had learned to self-administer fentanyl and went through extinction training did not reinstate drug-seeking behavior when administered PrNMI. DiscussionThe systemic CB1 receptor agonist PrNMI demonstrated analgesic benefit in alleviating mechanical allodynia associated with chronic constriction injury of the sciatic nerve without increasing addiction related behaviors associated with the establishment of addiction.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Nociceptor-restricted cannabinoid receptor 1 contributes to chronic but not acute analgesia
Amber L. Milligan, Audrey R Green, … Michael D. Burton·bioRxiv·Aug 21, 2026
- The cannabinoid agonist CB-13 produces peripherally mediated analgesia in mice but elicits tolerance and signs of CNS activity with repeated dosing
Richard A. Slivicki, Jiwon Yi, … Robert W. Gereau·PainPeer-reviewed·Dec 27, 2021
- Terpenes from Cannabis sativa Induce Antinociception in Mouse Chronic Neuropathic Pain via Activation of Spinal Cord Adenosine A2A Receptors
Abigail M. Schwarz, Attila I. Keresztes, … John M. Streicher·bioRxiv·Mar 28, 2023
- Cannabinoid CB2 receptors in primary sensory neurons are implicated in CB2 agonist-mediated suppression of paclitaxel-induced neuropathic nociception and sexually-dimorphic sparing of morphine tolerance
Kelsey G. Guenther, Xiaoyan Lin, … Andrea G. Hohmann·Biomedicine & PharmacotherapyPeer-reviewed·Jun 7, 2024
- Negative allosteric modulation of CB1 cannabinoid receptor signaling decreases intravenous morphine self-administration and relapse in mice
Idaira Oliva, Fezaan Kazi, … Andrea G. Hohmann·Addiction BiologyPeer-reviewed·Aug 1, 2024
- Peripheral sensory neuron CB2 cannabinoid receptors are necessary for both CB2-mediated antinociceptive efficacy and sparing of morphine tolerance in a mouse model of neuropathic pain
Lawrence M. Carey, Zhili Xu, … Andrea G. Hohmann·bioRxiv·May 16, 2022